Cargando…
Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies
OBJECTIVES AND AIMS: Disease modifying therapies used in multiple sclerosis can decrease humoral response after COVID-19 vaccines. This problem must be adequately addressed because new variants evolve, and COVID-19 still poses a risk to patients with comorbidities and immunosuppression. We aimed to...
Autores principales: | Baba, Cavid, Ozcelik, Sinem, Kaya, Ergi, Samedzada, Ulvi, Ozdogar, Asiye Tuba, Cevik, Sumeyye, Dogan, Yavuz, Ozakbas, Serkan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383952/ https://www.ncbi.nlm.nih.gov/pubmed/36037755 http://dx.doi.org/10.1016/j.msard.2022.104119 |
Ejemplares similares
-
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies
por: Ozakbas, Serkan, et al.
Publicado: (2022) -
Early Onset Multiple Sclerosis Has Worse Prognosis Than Adult Onset Multiple Sclerosis Based on Cognition and Magnetic Resonance Imaging
por: Ozakbas, Serkan, et al.
Publicado: (2012) -
Inflammatory Demyelinating Central Nervous System Diseases in Childhood: Clinical and Paraclinical Profiles in 133 Patients
por: Kaya, Derya, et al.
Publicado: (2012) -
Contingent Negative Variation Is Associated with Cognitive Dysfunction and Secondary Progressive Disease Course in Multiple Sclerosis
por: Uysal, Utku, et al.
Publicado: (2014) -
The Turkish validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery
por: Ozakbas, Serkan, et al.
Publicado: (2017)